Form 8-K - Current report:
SEC Accession No. 0001493152-23-022253
Filing Date
2023-06-23
Accepted
2023-06-23 16:19:56
Documents
17
Period of Report
2023-06-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36987
2 form8-k_001.jpg GRAPHIC 5681
3 ex99-1.htm EX-99.1 1996
4 ex99-1_001.jpg GRAPHIC 655341
5 ex99-2.htm EX-99.2 1465
6 ex99-2_001.jpg GRAPHIC 681051
  Complete submission text file 0001493152-23-022253.txt   2070845

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE lpcn-20230623.xsd EX-101.SCH 3015
8 XBRL LABEL FILE lpcn-20230623_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE lpcn-20230623_pre.xml EX-101.PRE 22359
11 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3317
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 231037953
SIC: 2834 Pharmaceutical Preparations